GLUT2 Mut-int iPSCs
QBRIi007-A
General
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Is the medical history available upon request? | Yes |
| Is clinical information available? | Yes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA6598024 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Please provide contact information of the holder of the original Donor Information Sheet. | Dr. Khalid Hussain (khussain@sidra.org) |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | Dr. Khalid Hussain (khussain@sidra.org) |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | Understanding the genetic mechanisms of diabetes mellitus |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | No |
| Does consent expressly permit collection of genetic information? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Institutional Review Board (IRB) Committee of Sidra Medicine and Qatar Biomedical Research Institute (QBRI) |
| Approval number | Sidra Medicine (no. 1702007608) and QBRI (no. 2018-002) |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Institutional Review Board (IRB) Committee of Sidra Medicine and Qatar Biomedical Research Institute (QBRI) |
| Approval number | Sidra Medicine (no. 1702007608) and QBRI (no. 2018-002) |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
Yes |
| Methods used |
PCR, RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SOX2 |
Yes |
|
|
|
||
| NANOG |
Yes |
|
|
|
||
| TRA 1-81 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
|
|
||
| Alkaline Phosphatase |
Yes |
|
Self-renewal
Unknown
Endoderm
Unknown
Mesoderm
Unknown
Ectoderm score
Positive
Differentiation Potency
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XX [cp20]
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.